Stratos Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Stratos Wealth Advisors's VRTX Position: Q2 2026 in Review
Stratos Wealth Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 421 shares worth $209K. The stake represents 0.01% of the portfolio and ranks #605 among its holdings. This is a return to the name: Stratos Wealth Advisors previously reported a position in VRTX as recently as Q4 2025.
Stratos Wealth Advisors first reported a position in VRTX in Q2 2024 and has held it in 6 quarters since. The position peaked at $260K in Q3 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Stratos Wealth Advisors held 421 shares of Vertex Pharmaceuticals worth $209K as of Q2 2026.
- Vertex Pharmaceuticals was a new Stratos Wealth Advisors position in Q2 2026.
- Vertex Pharmaceuticals made up 0.01% of Stratos Wealth Advisors's portfolio in Q2 2026, its #605 holding.
- Stratos Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
- Stratos Wealth Advisors's Vertex Pharmaceuticals position peaked at $260K in Q3 2024.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Stratos Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.